Treatment of hepatitis C
From Proteopedia
(Difference between revisions)
(New page: <StructureSection load='' size='340' side='right' caption='Sofosbuvir' scene='95/954110/Cv/1'> *Sofosbuvir </StructureSection> == References == <references/>) |
|||
| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Sofosbuvir' scene='95/954110/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Sofosbuvir' scene='95/954110/Cv/1'> | ||
| - | *[[Sofosbuvir]] | + | *[[Sofosbuvir]]. It is metabolized to the active antiviral agent <scene name='95/954110/Cv/2'>GS-461203</scene> (2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate). GS-461203 serves as a defective substrate for the [[NS5B]] protein, which is the viral [[RNA polymerase]], thus acts as an inhibitor of viral RNA synthesis. |
| + | *[[Telaprevir]] inhibits the hepatitis C viral enzyme NS3/4A serine protease. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Current revision
| |||||||||||
